España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Recent
Markets
Exondys 51
Sarepta Plunges After FDA Spurns Its Second Duchenne Muscular Dystrophy Drug
Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics
Sarepta's Beat And Raise Streak Continues
Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics
Sarepta's Beat And Raise Streak Continues
Sarepta's Upside Story Is Just Getting Started
U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'
Sarepta's Upside Story Is Just Getting Started
|
U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'
|
Sarepta Marks A 'Very Important Day' For The DMD Community
|
Down 16% Over May, Has Sarepta Become A Cheap Takeout Target?
|
Read More...
Exondys 51 Recent News
Exclusive: Capricor CEO Talks Exondys Competition
|
Here's Why Sarepta Therapeutics May Be The Rarest Of Finds: A 'Value' Biotech Stock
|
Sarepta Gets An Upgrade; Cardiac, Pulmonary Function Could Provide Added Clinical Support For Exondys
|
The Street Is Misreading Sarepta's Guidance
|
Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results
|
FDA 101: What Does 'Orphan Drug Designation' Mean?
|
For Sapreta, Today's Good News Might Be Just The Beginning
|
Sarepta Soars Following Encouraging Exondys 51 News
|
Credit Suisse Says Sarepta Shares Volatile, Still A Favorite Idea
|
2016's Most Hyped Events: How Did It Work Out For The Stocks?
|
The Rise And Fall Of Sarepta's Stock Since Exondys 51 Accelerated Approval
|
Sarepta's Launch Of Exondys 51 Likely Slower Than Expected As Payers Deny Or Restrict Coverage
|
New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51
|
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
|
3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'
|
For Sarepta, Exondys 51 Might Be Just The Beginning: Credit Suisse Starts At Outperform
|
Sarepta Shares Continue Rally As Analysts Flip To Positive
|
Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform
|